JG
ADPT icon

Jefferies Group’s Adaptive Biotechnologies ADPT Stock Holding History

Jefferies Group’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,095
Closed -$64.2K – 1592
2021
Q3 		$71.2K Buy
+2,095
New +$75.8K ﹤0.01% 1578
2019
Q4 		– Sell
-12,596
Closed -$389K – 2516
2019
Q3 		$389K Buy
+12,596
New +$514K ﹤0.01% 2016

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Jefferies Group's ADPT Position: Q4 2021 in Review

Jefferies Group sold out of Adaptive Biotechnologies (ADPT) in Q4 2021, closing a stake of 2,095 shares — an estimated $64.2K sold.

Jefferies Group first reported a position in ADPT in Q3 2019 and held it in 2 quarters. The position peaked at $389K in Q3 2019. 214 funds tracked by Wall St. Rank hold ADPT as of Q4 2021.

  • Jefferies Group reported no remaining Adaptive Biotechnologies position as of Q4 2021 after selling out during the quarter.
  • Jefferies Group sold 2,095 Adaptive Biotechnologies shares in Q4 2021, an estimated $64.2K.
  • Jefferies Group first reported a position in Adaptive Biotechnologies in Q3 2019 and held it in 2 quarters.
  • Jefferies Group's Adaptive Biotechnologies position peaked at $389K in Q3 2019.
  • 214 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2021.

Based on Jefferies Group's 13F filing for Q4 2021, filed 14 Feb 2022.